Latest FY 2026 earnings snapshot
Mesa Laboratories (MLAB) just closed FY 2026 with fourth quarter revenue of US$63.7 million and a loss per share of US$0.75, as net income excluding extra items came in at a loss of US$4.1 million. Over the past year the company has seen quarterly revenue move from US$62.1 million in FY 2025 Q4 to US$63.7 million in FY 2026 Q4, while quarterly EPS has swung between a loss of US$1.31 and a profit of up to US$0.87. This combination of improving trailing profitability and a still choppy quarterly EPS line puts the focus squarely on how durable Mesa Laboratories' margins really are.
See our full analysis for Mesa Laboratories.With the headline numbers set, the next step is to line them up against the dominant narratives around Mesa Laboratories to see which stories fit the data and which start to look out of date.
Curious how numbers become stories that shape markets? Explore Community Narratives
TTM EPS turns positive at US$1.22
- Over the last twelve months, Mesa Laboratories moved from a trailing loss to trailing EPS of US$1.22, alongside TTM net income of US$6.7 million on US$249.1 million of revenue, compared with a TTM loss of US$1.97 million on US$241.0 million of revenue a year earlier.
- Bulls often focus on this shift to profitability, and the numbers give them some support but also some context:
- On the supportive side, trailing net income moved from a loss of US$1.97 million in FY 2025 Q4 TTM to a profit of US$6.7 million in FY 2026 Q4 TTM, while TTM revenue lifted from US$241.0 million to US$249.1 million over the same window.
- Balancing that, the five year earnings history still points to average EPS contraction of 37.2% per year, so anyone taking a bullish stance is leaning on the most recent period rather than a long multi year pattern.
Investors who want to see how this new profitability profile fits into a broader long term story can tap into community views through Curious how numbers become stories that shape markets? Explore Community Narratives.
High P/E of 74.7x versus peers
- The stock trades on a trailing P/E of 74.7x against a peer average P/E of a loss making figure around 10.5x and a Global Life Sciences industry average of 33.8x. This means the multiple is more than double the broader industry level based on the provided data.
- Skeptics point to this high multiple as a bearish talking point, and the figures highlight why they focus on it:
- Compared with the current share price of US$90.80, the elevated 74.7x P/E is being applied to trailing EPS of just US$1.22, which is a relatively small profit base given the company’s past five year average earnings contraction of 37.2% per year.
- Even though peers on average show a loss making P/E figure, the Global Life Sciences industry sits at 33.8x on the same metric. Critics therefore argue Mesa Laboratories is priced at more than 2x that industry reference while still carrying a mixed longer term earnings record.
DCF fair value far above market price
- The supplied DCF fair value of US$184.26 per share stands well above the current share price of US$90.80. Based on the inputs given, this places the stock about 50.7% below that DCF estimate.
- Supporters who lean on this DCF gap frame it as a bullish signal, and the earnings data helps explain why they pay attention to it:
- TTM revenue has moved from US$241.0 million to US$249.1 million while TTM net income turned from a loss of US$1.97 million to a profit of US$6.7 million, so the model is built on a period where operations are now contributing positive earnings.
- At the same time, the stock’s P/E of 74.7x and a five year average decline in earnings of 37.2% per year show why some investors may be cautious about leaning only on the DCF fair value, since the market is still applying a rich earnings multiple to a relatively recent profit turnaround.
Next Steps
Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Mesa Laboratories's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.
If the mixed signals in the numbers leave you on the fence, that is a useful starting point. It pushes you to check the details and move quickly while the story is still forming around fresh results and sentiment shifts, then weigh those against the 2 key rewards
See What Else Is Out There
Mesa Laboratories carries a rich 74.7x P/E on a relatively modest recent profit turnaround and a five year record of average EPS contraction of 37.2% per year.
If that mix of a high earnings multiple and uneven profit history makes you cautious, compare it with companies screened for stronger value signals using 46 high quality undervalued stocks.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com